良性前列腺增生的医学处理。

Geriatric nephrology and urology Pub Date : 1999-01-01 DOI:10.1023/a:1008308819463

A Chacon, M Monga

{"title":"良性前列腺增生的医学处理。","authors":"A Chacon, M Monga","doi":"10.1023/a:1008308819463","DOIUrl":null,"url":null,"abstract":"The management of benign prostatic hyperplasia has undergone a rapid evolution over the past decade from a surgical emphasis to a medical emphasis. Great strides in the development of alpha-adrenergic blockers, 5 alpha-reductase inhibitors and a variety of phytotherapeutics have fueled this evolution. This article reviews the past, present and future of the medical management of benign prostatic hyperplasia.","PeriodicalId":79490,"journal":{"name":"Geriatric nephrology and urology","volume":"9 1","pages":"39-48"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1023/a:1008308819463","citationCount":"19","resultStr":"{\"title\":\"Medical management of benign prostatic hyperplasia.\",\"authors\":\"A Chacon, M Monga\",\"doi\":\"10.1023/a:1008308819463\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The management of benign prostatic hyperplasia has undergone a rapid evolution over the past decade from a surgical emphasis to a medical emphasis. Great strides in the development of alpha-adrenergic blockers, 5 alpha-reductase inhibitors and a variety of phytotherapeutics have fueled this evolution. This article reviews the past, present and future of the medical management of benign prostatic hyperplasia.\",\"PeriodicalId\":79490,\"journal\":{\"name\":\"Geriatric nephrology and urology\",\"volume\":\"9 1\",\"pages\":\"39-48\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1023/a:1008308819463\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Geriatric nephrology and urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1023/a:1008308819463\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Geriatric nephrology and urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1023/a:1008308819463","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 19

摘要

在过去的十年中，良性前列腺增生的治疗经历了从外科手术到医学治疗的快速发展。α -肾上腺素能阻滞剂、α -还原酶抑制剂和各种植物疗法的巨大进步推动了这一进化。本文综述了良性前列腺增生的医学治疗的过去、现在和未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Medical management of benign prostatic hyperplasia.

The management of benign prostatic hyperplasia has undergone a rapid evolution over the past decade from a surgical emphasis to a medical emphasis. Great strides in the development of alpha-adrenergic blockers, 5 alpha-reductase inhibitors and a variety of phytotherapeutics have fueled this evolution. This article reviews the past, present and future of the medical management of benign prostatic hyperplasia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Geriatric nephrology and urology

自引率

0.00%

发文量